Clinicopathological description of two cases with SQSTM1 gene mutation associated with frontotemporal dementia
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
There is a strong genetic influence on the clinicopathological phenotypes associated with frontotemporal lobar degeneration (FTLD) and frontotemporal dementia (FTD). Intracellular deposition of TDP‐43 is the phenotypical hallmark of a frequent subgroup of cases. Mutations in the sequestosome 1 ( SQSTM1 ) gene have rarely been found in individuals with FTD. Here we provide a comprehensive clinicopathological description of two cases with a SQSTM1 mutation. The clinical phenotype of patient 1 (mutation p.Glu396*) was compatible with the behavioural variant (bv) of FTD. TDP‐43 pathology was consistent with the features of type B of FTLD‐TDP pathology. However, prominent neuronal granular cytoplasmic TDP‐43 immunoreactivity and abundant oligodendroglial inclusions, proven by colocalization with the oligodendroglial‐marker TPPP/p25, were also seen. The clinical phenotype of patient 2 was compatible with bvFTD associated with parkinsonism and bulbar symptoms in the later stage. Genetic testing of patient 2 identified a C9orf72 repeat expansion mutation together with a missense mutation (p.Arg212Cys) in SQSTM1 . TDP‐43 pathology was characterized by neuritic profiles compatible mostly with type A. In contrast to patient 1, p62 pathology was seen to a greater extent as TDP‐43 immunoreactivity in neurons. Using an antibody that detects poly(GP) peptides produced via repeat associated non‐ATG translation associated with expanded hexanucleotide repeat in the C9orf72 gene, we confirmed the presence of pathognomonic inclusions. The present study supports previous observations on amyotrophic lateral sclerosis (ALS) that SQSTM1 mutations consistently associate with TDP‐43 pathology. The co‐presence of C9orf72 mutation may influence the phenotype, thus finding one FTLD (or ALS) related mutation does not exclude the presence of further influential genetic alterations. Oligodendroglial TDP‐43 pathology is considerable in some forms of FTLD‐TDP, thus their evaluation might be considered to be included in classification systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia
Deng, H.-X., Chen, W., Hong, S.-T., Boycott, K. M., Gorrie, G. H., Siddique, N., Yang, Y., Fecto, F., Shi, Y., Zhai, H., et al. (2011) · Nature · doi:10.1038/nature10353 · Cited by 1,174
Stages of pTDP‐43 pathology in amyotrophic lateral sclerosis
Brettschneider, J., Del Tredici, K., Toledo, J. B., Robinson, J. L., Irwin, D. J., Grossman, M., Suh, E., Van Deerlin, V. M., Wood, E. M., Baek, Y., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23937 · Cited by 1,065
Papp, M. I., Kahn, J. E., & Lantos, P. L. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90219-0 · Cited by 991 · cited 1×
“The globular nature of oligodendroglial inclusions in patient 1 somehow resembles that seen in the α-synucleinopathy multiple system atrophy(39) and in globular glial tauopathies;(40) however, in contrast to those, the present pTDP-43 oligodendroglial inclusions were not visible inGallyas staining.(41,42) Importantly,…”
Result<emph type="ital">SQSTM1</emph> Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
Fecto, F. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.250 · Cited by 650
Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.
Laurin, N., Brown, J. P., Morissette, J., & Raymond, V. (2002) · The American Journal of Human Genetics · doi:10.1086/340731 · Cited by 563
Two Types of Sporadic Cerebral Amyloid Angiopathy
Thal, D. R., Ghebremedhin, E., Rüb, U., Yamaguchi, H., Del Tredici, K., & Braak, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.3.282 · Cited by 446
Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy
Trojanowski, J. Q., Revesz, T., & the Neuropathology Working Group on MSA (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00907.x · Cited by 349
SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
Rubino, E., Rainero, I., Chiò, A., Rogaeva, E., Galimberti, D., Fenoglio, P., Grinberg, Y., Isaia, G., Calvo, A., Gentile, S., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e25df · Cited by 286
Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology
Teyssou, E., Takeda, T., Lebon, V., Boillée, S., Doukouré, B., Bataillon, G., Sazdovitch, V., Cazeneuve, C., Meininger, V., LeGuern, E., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1090-0 · Cited by 241 · cited 5×
“The present report on two cases expands the clinicopathological spectrum of SQSTM1mutations and demonstrates that pTDP-43 pathology is consistently associated with these genetic alterations, similar to published cases with ALS phenotype.(19,21) Neither of our patients had been investigated for PDB using biological tes…”
BackgroundResultInfluentialThe neuropathology associated with repeat expansions in the C9ORF72 gene
Mackenzie, I. R. A., Frick, P., & Neumann, M. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1232-4 · Cited by 206 · cited 5×
“A unique neuropathological feature in C9ORF72 mutation cases is the presence of neuronal inclusions that immunostain for markers of the ubiquitin proteasome system (UPS, such as ubiquitin and p62) but are negative for TDP-43.(10) Themajor components of these inclusions are dipeptide repeat proteins resulting from the…”
BackgroundResultInfluentialTanabe, F., Yone, K., Kawabata, N., Sakakima, H., Matsuda, F., Ishidou, Y., Maeda, S., Abematsu, M., Komiya, S., & Setoguchi, T. (2011) · Autophagy · doi:10.4161/auto.7.12.17892 · Cited by 85
Höftberger, R., Fink, S., Aboul‐Enein, F., Botond, G., Olah, J., Berki, T., Ovadi, J., Lassmann, H., Budka, H., & Kovacs, G. G. (2010) · Glia · doi:10.1002/glia.21054 · Cited by 79
Self-citationC9orf72 G4C2 repeat expansions in Alzheimer's disease and mild cognitive impairment
Cacace, R., Van Cauwenberghe, C., Bettens, K., Gijselinck, I., van der Zee, J., Engelborghs, S., Vandenbulcke, M., Van Dongen, J., Bäumer, V., Dillen, L., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.019 · Cited by 74
Cited by
Mackenzie, I. R. A., & Neumann, M. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13588 · Cited by 381
The role of Nrf2 signaling in counteracting neurodegenerative diseases
Dinkova‐Kostova, A. T., Kostov, R. V., & Kazantsev, A. G. (2018) · The FEBS Journal · doi:10.1111/febs.14379 · Cited by 342
Kovacs, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020189 · Cited by 321
Self-citationReview: neuropathology of non-tau frontotemporal lobar degeneration
Neumann, M., & Mackenzie, I. R. A. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12526 · Cited by 144
Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease
Chitramuthu, B. P., Bennett, H. P. J., & Bateman, A. (2017) · Brain · doi:10.1093/brain/awx198 · Cited by 138
“, 2004), SQSTM1 (sequestome 1/p62) (Le Ber et al., 2013; Kovacs et al., 2016), UBQLN2 (ubiquilin 2) (Deng et al.”
Metadata
- Authors
- Kovacs, G. G., van der Zee, J., Hort, J., Kristoferitsch, W., Leitha, T., Höftberger, R., Ströbel, T., Van Broeckhoven, C., & Matej, R.
- Venue
- Neuropathology
- Publisher
- Wiley
- Published
- 2015-08-03
- Volume
- 36
- Issue
- 1
- Pages
- 27-38
- ISSN
- 0919-6544 (ISSN-L)
- 1440-1789
- OpenAlex
- W1947712678
- Cited by
- 34
- References
- 14
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.